Carna Biosciences, Inc. (TYO:4572)

Japan flag Japan · Delayed Price · Currency is JPY
301.00
-11.00 (-3.53%)
At close: Feb 6, 2026
5.61%
Market Cap5.76B +4.7%
Revenue (ttm)544.45M -61.1%
Net Income-2.19B
EPS-114.82
Shares Out19.14M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume122,000
Average Volume482,205
Open304.00
Previous Close312.00
Day's Range297.00 - 309.00
52-Week Range200.00 - 512.00
Beta0.44
RSI38.61
Earnings DateFeb 10, 2026

About Carna Biosciences

Carna Biosciences, Inc., a clinical-stage biopharmaceutical company, discovers and develops drug therapies to treat unmet medical needs in Japan. Its products include kinase proteins and other protein products, including tyrosine, serine/threonine, lipid, inactive kinase, and pseudokinase; GST-tagged and Biotinylated; Protein Substrate; and Luciferase PPI Stable Cell Lines, such as GPCR and protein-protein interactions. The company also provides activity-based biochemical screening/profiling assay services comprising mobility shift assay/IMAP a... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2003
Employees 63
Stock Exchange Tokyo Stock Exchange
Ticker Symbol 4572
Full Company Profile

Financial Performance

In 2024, Carna Biosciences's revenue was 636.00 million, a decrease of -60.86% compared to the previous year's 1.63 billion. Losses were -2.18 billion, 89.1% more than in 2023.

Financial Statements